头孢菌素类抗菌药物3种方案治疗下呼吸道感染的最小成本分析

Cephalosporins for Lower Respiratory Infection: Cost-Minimization Analysis on 3 Schemes

目的评价3种头孢菌素类抗菌药物治疗下呼吸道轻、中度感染的经济学效果。方法142例下呼吸道感染患者随机分为A、B、C组,分别给予头孢曲松钠、头孢噻肟钠、头孢呋辛钠治疗,观察各组疗效、不良反应,并进行最小成本分析。结果A、B、C组有效率分别为81%、83%、79%(P>0.05);总成本分别为(845.66±55.01)、(1065.78±96.26)、(1229.31±111.63)元(P<0.05)。结论头孢曲松钠治疗下呼吸道感染经济性较佳。

OBJECTIVE： To evaluate the pharmacoeconomic efficacies of 3 kinds of cephalosporins（CEPs） for low and middle- grade lower respiratory infections.METHODS：A total of 142 patients with lower respiratory infections were randomly assigned to receive ceftriaxone sodium（group A）, cefotaxime sodium（group ]3） and cefuroxime sodium（group C）, the efficacies and adverse drug reactions（ADRs） of the 3 groups were monitored and on which cost minimization analyses were performed. RESULTS： The total effective rates of group A, B, and C were 81%, 83% and 79%, respectively（P 〉0.05） ; The total cost of t he 3 groups were （845.66 ± 55.01）yuan, （1 065.78 ±96.26）yuan and （1 229.31 ± 111.63）yuan, respectively （P〈0.05）.CONCLUSION： Ceftriaxone sodium is the optimal one for lower respiratory infection in pharmacoeconomics.